Table 1.

In vivo tumorigenicity of ovarian tumor sphere-forming cells

Sample/cell typeCell dose *Injection siteTumor formation Latency (d) Serial transplantation rate
T1
    Sphere-forming100S.c.2/286, 1025/5
1,000S.c.2/274, 81
10,000S.c.2/260, 77
    Bulk tumor10,000S.c.0/2
100,000S.c.0/2
1,000,000S.c.0/2
    Differentiated10,000S.c.0/2
100,000S.c.0/2
1,000,000S.c.1/284
T2
    Sphere-forming100S.c.2/273, 965/5
1,000S.c.2/265, 75
10,000S.c.2/262, 69
5,000I.p.1/1753/3
    Bulk tumor10,000S.c.0/2
100,000S.c.0/2
1,000,000S.c.0/2
50,000I.p.0/1
500,000I.p.0/1
    Differentiated10,000S.c.0/2
100,000S.c.0/2
1,000,000S.c.1/292
50,000I.p.0/1
500,000I.p.0/1
  • * Number of cells per injection.

  • Number of tumors formed per number of injection.

  • The time from injection to the first appearance of a palpable tumor.